The shutdown is straining the FDA

FDA commissioner Scott Gottlieb in a chair
FDA Commissioner Scott Gottlieb. Photo: Chip Somodevilla/Getty Images

The partial government shutdown is beginning to cramp the Food and Drug Administration’s ability to review new drugs, and those effects will only grow more pronounced if the shutdown continues to drag on.

Driving the news: Aimmune Therapeutics, a company that’s seeking approval for a new drug to help children with peanut allergies, said in a financial filing yesterday that the FDA won’t be able to review its product until the government reopens.

2 major insulin makers hike U.S. prices at least 4%

A production line of insulin at a Novo Nordisk factory.
A production line of insulin at a Novo Nordisk factory. Photo: Jean-Francois Monier/AFP/Getty Images

Sanofi and Novo Nordisk, 2 of the 3 major insulin makers that dominate the global market, have raised the prices of their medications in the U.S. by at least 4%, depending on the particular insulin, the Financial Times reports.

The big picture: The companies say the hikes cover rebates paid to middlemen. Eli Lilly, the third major manufacturer, has not raised the price of its insulin products and did not immediately comment to Axios about whether it planned to do so this year.

Go deeper: The outrage over insulin prices

More stories loading.